Logo image
Se connecter
12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation
Article de revue   Avec comité de lecture

12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Pauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, Caroline Jezequel, Christophe Duvoux, Victor de Ledinghen, Sylvie Radenne, Nassim Kamar, Vincent Leroy, Vincent Di Martino, …
Hepatology (Baltimore, Md.), Vol.68(4), pp.1277-1287
10/04/2018
PMID: 29633389

Résumé

Life Sciences
Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).

Indicateurs

1 Consultations de la notice

Détails

Logo image